Michigan Progressive Health is now offering
Group Oral Ketamine Treatment 
(Royal Oak location only)

This is a program pioneered by Dr. Alison Mclnnes and Kaiser Permanente in California and adapted by MPH to help make ketamine treatment more affordable and accessible in the Metro Detroit area.

  • Ketamine will be administered in our office in a group setting twice a week: Tuesday & Friday mornings.
  • Participants will receive their dose of ketamine in a group setting with an experienced therapist and clinic provider. The group setting allows patients a safe environment to share their experience with both illness and improvement as treatment progresses.
  • When administered in this setting, our clinics experience has been that oral ketamine can be as effective as IV ketamine in the right patient population.
  • The program will be four weeks long. Ideally, we will give each participant a prescription for a safe, effective dose of oral ketamine to be continued at home after program completion.
  • For more information click on the link above or call the Royal Oak office at 248-291-7709.

Megan Hart, MA LLP

Megan is a seasoned psychotherapist, educator and patient advocate.  After receiving her MA in Clinical Psychology from the University of Detroit Mercy, Megan went onto to perform various roles providing and overseeing direct service delivery to both adult and children treatment populations recovering from serious mental illness.

As a limited licensed psychologist and certified advanced alcohol and drug counselor, Megan adheres to a harm reduction approach to treatment with specialized clinical expertise in addiction, motivational interviewing, stage-wise treatment interventions, self-injurious behaviors and suicide prevention/awareness.  As the facilitator of our group psychotherapy sessions, Megan’s focus is to foster collaborative discussions that build upon individual strengths and mobilize our client’s personal resources to promote positive, long-term behavioral change.

SCIENTIFIC ARTICLES

Does oral administration of ketamine accelerate response to treatment in major depressive disorder?

Arabzadeh, S. et al.  “Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial”.  Journal of Affective Disorders. 2018 Aug 1;235:236-241

https://www.ncbi.nlm.nih.gov/pubmed/29660637

SUMMARY:  In this study 81 patients were randomized to two groups.  150mg of sertraline plus 50mg of daily oral ketamine and 150mg of sertraline and placebo.  The oral ketamine cohort had a statistically significant mood improvement (85.4%) as compared to the placebo group (42.5%) as measured by HADRS at 2,4 and 6 weeks.  For both groups, side effects were mild and the frequency was the same between groups. No patients developed abuse or dependence to ketamine.

Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study

Hartberg, J et al.  “Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study.”  Psychopharmacology. 2018 Feb;235(2):393-398

https://www.ncbi.nlm.nih.gov/pubmed/29151192

SUMMARY:  In this study, 37 patients with TRD (15 of whom had PTSD as their primary diagnosis) were given oral ketamine twice a week.  Doses started at .5mg/kg orally and were titrated to effect. After initiation of ketamine therapy, the participants had a 70% reduction in hospital admissions.  The average dose was ultimately 2.0mg/kg twice a week. There was no evidence of tolerance. No serious adverse events were recorded among patients. The most common side effects were light-headedness, sedation and mild dissociative effects.  Remarkably, there was typically a decrease in the amount of ketamine needed over time.